Bristol-Myers Squibb Company Ce Fundamental Analysis
Bristol-Myers Squibb Company Ce Fundamental Analysis
Bristol-Myers Squibb Company Ce (CELG-RI) shows weak financial fundamentals with a PE ratio of N/A, profit margin of N/A, and ROE of 61.86%. The company generates $42.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 44.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CELG-RI's fundamental strength across five key dimensions:
Efficiency Score
WeakCELG-RI struggles to generate sufficient returns from assets.
Valuation Score
WeakCELG-RI trades at a premium to fair value.
Growth Score
WeakCELG-RI faces weak or negative growth trends.
Financial Health Score
ModerateCELG-RI shows balanced financial health with some risks.
Profitability Score
ModerateCELG-RI maintains healthy but balanced margins.
Key Financial Metrics
Is CELG-RI Expensive or Cheap?
Price to Book
The market values Bristol-Myers Squibb Company Ce at 0.00 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.00 times EBITDA. This is generally considered low.
Debt/Equity
Bristol-Myers Squibb Company Ce has a debt-to-equity ratio of 3.29, indicating its leverage.
P/FCF
The Price to Free Cash Flow ratio of 0.00 shows how the market values its ability to generate cash.
How Well Does CELG-RI Make Money?
ROE
Management delivers $61.86 in profit for every $100 of shareholder equity.
ROA
Bristol-Myers Squibb Company Ce generates $35.92 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bristol-Myers Squibb Company Ce generates strong operating cash flow of $14.39B, reflecting robust business health.
Free Cash Flow
Bristol-Myers Squibb Company Ce generates strong free cash flow of $13.47B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.60 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
N/A
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
N/A
vs 25 benchmark
P/B Ratio
Price to book value ratio
N/A
vs 25 benchmark
P/S Ratio
Price to sales ratio
N/A
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
N/A
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.62
vs 25 benchmark
ROA
Return on assets percentage
N/A
vs 25 benchmark
ROCE
Return on capital employed
N/A
vs 25 benchmark
How CELG-RI Stacks Against Its Sector Peers
| Metric | CELG-RI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | N/A | 34.27 | N/A |
| ROE | 61.86% | 377.00% | Weak |
| Net Margin | N/A | -42945.00% (disorted) | N/A |
| Debt/Equity | 3.29 | 0.78 | Weak (High Leverage) |
| Current Ratio | N/A | 5.54 | N/A |
| ROA | N/A | -162.00% (disorted) | N/A |
CELG-RI outperforms its industry in 0 out of 2 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bristol-Myers Squibb Company Ce's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation